Discoid Lupus Erythematosus (DLE)

🧠 Standard of Care & Symptoms

Discoid Lupus Erythematosus (DLE) is the most common subtype of chronic cutaneous lupus erythematosus (CCLE). It is an autoimmune skin condition that leads to scarring, pigment changes, and hair loss if left untreated.

• Presentation: Key diagnostic signs.
  • *Disc-Shaped Plaques:* Well-demarcated, round or oval erythematous plaques, most commonly occurring on sun-exposed skin (face, ears, neck, scalp).
  • *Adherent Scaling & Follicular Plugging:* The surface of active lesions shows a dry, adherent scale that extends into dilated hair follicles. Peeling back the scale reveals tiny projections resembling carpet tacks (**"carpet tack" sign**).
  • *Central Atrophy & Scarring:* Older lesions exhibit central clearing with thinning of the skin (atrophy), permanent scarring, and loss of normal pigment (depigmentation), surrounded by a hyperpigmented, active border.
  • *Scarring Alopecia:* Scalp involvement leads to permanent hair follicle destruction and patch-like baldness.

🧬 Diagnostics & Autoimmune Pathophysiology

Diagnosis is based on clinical inspection, a punch skin biopsy, and direct immunofluorescence testing to verify localized antibody deposition.

• Diagnostic Markers: Key criteria.
  • Skin Biopsy: Demonstrates hyperkeratosis with follicular plugging, vacuolar degeneration of the basal cell layer, basement membrane thickening, and a dense, perivascular and periadnexal lymphocytic infiltrate in the dermis.
  • Direct Immunofluorescence (DIF): Reveals a granular band-like deposition of immunoglobulin G (IgG), IgM, and complement C3 along the dermo-epidermal junction. This is diagnostic and referred to as the **lupus band test**.
  • Systemic Screening: While DLE is restricted to the skin, ~10-15% of patients may develop Systemic Lupus Erythematosus (SLE). Evaluation includes tests for Antinuclear Antibodies (ANA), CBC, and urinalysis to monitor for systemic progression.

Pathophysiology of Cutaneous Lupus

The scarring lesions of DLE are driven by a localized autoimmune reaction directed against skin cells:

• Type I Interferon (IFN) Pathway: Keratinocytes in DLE lesions produce high baseline levels of **Type I Interferons (IFN-alpha and IFN-beta)**. These interferons promote the expression of chemokines (CXCL9, CXCL10), recruiting cytotoxic CD8+ T cells to the skin.
• Cytotoxic Interface Dermatitis: Activated CD8+ T cells target the basement membrane, causing vacuolar degeneration and apoptosis of basal keratinocytes. This cellular death leads to basement membrane thickening and scarring.
• UV-Induced Apoptosis: Ultraviolet (UV) light stimulates keratinocytes to undergo apoptosis, exposing nuclear antigens (such as Ro/SSA) on the cell surface. This triggers localized autoantibody binding and initiates the inflammatory cascade.

💊 Photoprotection & Medical Therapies

Treatment focuses on controlling active plaques, preventing scarring alopecia, and utilizing strict sun avoidance protocols.

Strict Photoprotection

• Broad-Spectrum Sunscreens: Daily application of mineral-based sunscreens (zinc oxide or titanium dioxide) with SPF 50+ is mandatory, even on cloudy days or indoors.
• UV Barrier Clothing: Patients should wear wide-brimmed hats and UPF 50+ rated clothing to protect skin from UV-triggered auto-antigen exposure.

Topical & Systemic Medications

• Topical & Intralesional Steroids: High-potency topical steroids (Clobetasol propionate) or intralesional triamcinolone acetonide injections (2.5-5 mg/mL) are first-line therapies for active, localized lesions and scalp involvement to prevent hair loss.
• Topical Calcineurin Inhibitors: Tacrolimus (0.1% ointment) is used as a steroid-sparing agent, particularly on the face, to avoid steroid-induced skin thinning (atrophy) or telangiectasias.
• Oral Antimalarials (Hydroxychloroquine): First-line systemic therapy. **Hydroxychloroquine** (not exceeding 5 mg/kg/day of actual body weight) reduces UV-induced skin sensitivity and blocks Toll-like receptor signaling. Regular ophthalmologic screening is required to prevent retinal toxicity.

🔬 Active Clinical Trials

Clinical trials are currently evaluating targeted type I interferon inhibitors, TYK2 inhibitors, and next-generation topical immunomodulators.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with Discoid Lupus Erythematosus, establish these clinical care pathways:

1. Review Photoprotection Habits: Invest in UPF 50+ clothing and transition to physical (mineral) sunscreens containing Zinc Oxide or Titanium Dioxide.
2. Establish Systemic Screening: Complete a baseline ANA test, complete blood count (CBC), and urinalysis with your doctor to rule out systemic involvement (SLE).
3. Discuss Antimalarial Options: If starting Hydroxychloroquine, schedule an initial dilated eye exam to establish a baseline for retinal safety.
4. Avoid Skin Trauma (Koebner Phenomenon): Minimize skin injuries, scratches, or cosmetic chemical peels, as DLE lesions can develop at sites of minor trauma.

❓ Patient FAQ

Q: Does discoid lupus turn into systemic lupus (SLE)?
A: In the majority of cases, DLE remains restricted to the skin. However, approximately 10 to 15% of patients with DLE may eventually develop systemic lupus (SLE). Regular laboratory follow-ups and reporting systemic symptoms (such as joint pain or extreme fatigue) are important.

Q: Will hair lost from discoid scalp lesions grow back?
A: Unfortunately, because DLE causes scarring (cicatricial) alopecia, the hair follicles in long-standing, scarred lesions are permanently destroyed and cannot regrow hair. Early, aggressive treatment with steroid injections is crucial to stop active inflammation before permanent scarring occurs.